Literature DB >> 16974184

Randomized, double-blind 6-month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning.

Bruce J Kinon1, Douglas L Noordsy, Hong Liu-Seifert, Angela H Gulliver, Haya Ascher-Svanum, Sara Kollack-Walker.   

Abstract

This study compared the effects of olanzapine (OLZ) with those of quetiapine (QUE) for improving negative symptoms in patients diagnosed with schizophrenia or schizoaffective disorder who had prominent negative symptoms and marked deficits in social or occupational functioning. In this 6-month, multicenter, double-blind clinical trial, patients were randomized to treatment with OLZ (n = 171, 10-20 mg/d) or QUE (n = 175, 300-700 mg/d). Patients were treated at community mental health centers and assigned case managers who developed individualized psychosocial treatment plans. The primary efficacy measure was the reduction in negative symptoms using the Scale for the Assessment of Negative Symptoms. Secondary measures assessed changes in functioning, psychopathology, and treatment tolerability. Treatment with OLZ or QUE led to a significant reduction in negative symptoms, with no between-group difference (P = 0.09). Both treatment groups also showed significant improvement on most efficacy measures. Olanzapine-treated patients showed significantly greater improvement on positive symptoms and on several measures of functioning including Global Assessment of Functioning Scale, Quality of Life Instrumental Role domain, and level of effort in psychosocial or occupational rehabilitation programs. Significantly more OLZ-treated patients completed the study (52.6% OLZ, 37.7% QUE, P = 0.007). Treatment differences in safety were relatively small and not thought to be clinically relevant. Patients with schizophrenia who manifest prominent negative symptoms and marked functional deficits demonstrated significant improvement in negative symptoms after treatment with OLZ or QUE. Greater improvement in positive symptoms and a greater study completion rate may hold relevance to enhanced functional outcomes observed after OLZ therapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16974184     DOI: 10.1097/01.jcp.0000236658.16286.25

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  20 in total

Review 1.  Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder.

Authors:  Leslie Citrome; Richard I G Holt; Daniel J Walker; Vicki Poole Hoffmann
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

2.  Long-term effectiveness of oral second-generation antipsychotics in patients with schizophrenia and related disorders: a systematic review and meta-analysis of direct head-to-head comparisons.

Authors:  Taishiro Kishimoto; Katsuhiko Hagi; Masahiro Nitta; John M Kane; Christoph U Correll
Journal:  World Psychiatry       Date:  2019-06       Impact factor: 49.548

3.  Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis.

Authors:  Maren Carbon; John M Kane; Stefan Leucht; Christoph U Correll
Journal:  World Psychiatry       Date:  2018-10       Impact factor: 49.548

Review 4.  Antipsychotic Management of Schizoaffective Disorder: A Review.

Authors:  Jean-Pierre Lindenmayer; Amandeep Kaur
Journal:  Drugs       Date:  2016-04       Impact factor: 9.546

Review 5.  Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis.

Authors:  Marc Krause; Yikang Zhu; Maximilian Huhn; Johannes Schneider-Thoma; Irene Bighelli; Adriani Nikolakopoulou; Stefan Leucht
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2018-01-24       Impact factor: 5.270

Review 6.  Olanzapine versus other atypical antipsychotics for schizophrenia.

Authors:  Katja Komossa; Christine Rummel-Kluge; Heike Hunger; Franziska Schmid; Sandra Schwarz; Lorna Duggan; Werner Kissling; Stefan Leucht
Journal:  Cochrane Database Syst Rev       Date:  2010-03-17

7.  How Many Patients With Schizophrenia Do Not Respond to Antipsychotic Drugs in the Short Term? An Analysis Based on Individual Patient Data From Randomized Controlled Trials.

Authors:  Myrto T Samara; Adriani Nikolakopoulou; Georgia Salanti; Stefan Leucht
Journal:  Schizophr Bull       Date:  2019-04-25       Impact factor: 9.306

8.  Modulation of human motor cortex excitability by quetiapine.

Authors:  Berthold Langguth; Peter Eichhammer; Claus Spranz; Michael Landgrebe; Ulrich Frick; Philipp Sand; Göran Hajak
Journal:  Psychopharmacology (Berl)       Date:  2007-11-23       Impact factor: 4.530

9.  Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States.

Authors:  Nicolas M Furiak; Haya Ascher-Svanum; Robert W Klein; Lee J Smolen; Anthony H Lawson; Robert R Conley; Steven D Culler
Journal:  Cost Eff Resour Alloc       Date:  2009-04-07

10.  Adherence and persistence to typical and atypical antipsychotics in the naturalistic treatment of patients with schizophrenia.

Authors:  Haya Ascher-Svanum; Baojin Zhu; Douglas E Faries; Jonathan P Lacro; Christian R Dolder; Xiaomei Peng
Journal:  Patient Prefer Adherence       Date:  2008-02-02       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.